Determining Efficacy of an Artificial Intelligence-based System for Heart Failure Detection Through Interpretation of Electrocardiograms (DECISION)

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age65+
SponsorIdoven 1903 S.L.

About this trial

The DECISION trial aims to evaluate the efficacy of an artificial intelligence (AI)-powered system, Willem™, for improving the detection of heart failure (HF) in primary care settings by interpreting electrocardiograms (ECGs). The study seeks to answer whether AI-assisted ECG interpretation enhances diagnostic accuracy and clinical outcomes compared to standard ECG evaluation in patients with suspected HF or those at high risk.

This multicenter, pragmatic, randomized clinical trial involves two groups: patients receiving AI-assisted ECG analysis and those undergoing standard ECG evaluation. The study's primary analysis will compare the diagnostic performance of AI-assisted ECG versus standard ECG using sensitivity, specificity, and predictive value metrics. Secondary analyses will evaluate healthcare resource utilization, clinical outcomes, and usability feedback from healthcare providers. Results will inform the potential integration of AI-assisted ECG in routine primary care workflows for earlier HF detection and better resource allocation.

Eligibility criteria

Qualifiers

Able to understand and accept the study constraints and to provide informed consent (either themselves or a legal representative).

Age over 65 years (i.e., 65 included).

Presence of symptoms and/or signs typical of Heart Failure (defined by the European Society of Cardiology, ESC), including breathlessness (during activity or at rest, lying down, waking up at night needing to catch their breath), fatigue, swollen ankles/legs, and/or palpitations.

Able to understand and accept the study constraints and to provide informed consent (either themselves or a legal representative).

Disqualifiers

Unwillingness or inability to sign the written informed consent.

Previous Heart Failure diagnosis.

Unavailability or suboptimal quality ECG.

Trial design

Treatments tested in this trial

  • Willem™ platform ECG assessment

Treatment groups

1,968 Participants
are divided into 2 treatment groups

Locations

5
Spain
Hospital General Universitario Gregorio Marañón Madrid Spain
Hospital Universitario 12 de Octubre Madrid Spain
Primary Care: Gerencia Asistencial Atención Primaria Madrid Madrid Spain
Hospital Universitario Marqués de Valdecilla Santander Spain

Sponsors and collaborators

Idoven 1903 S.L.

Lead sponsor

Fundación para la Investigación Biomédica del Hospital 12 de Octubre

Collaborator

Fundación para la Investigación Biomédica del Hospital Gregorio Maranon

Collaborator

Fundación para la Investigación e Innovación Biosanitaria de Atención Primaria de la Comunidad de Madrid (FIIBAP)

Collaborator

Instituto de Investigación Marqués de Valdecilla

Collaborator

Karolinska Institutet

Collaborator

Region Stockholm

Collaborator

AstraZeneca

Collaborator

Servicio Madrileno De Salud (SERMAS)

Collaborator